MX2015012520A - Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion. - Google Patents

Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion.

Info

Publication number
MX2015012520A
MX2015012520A MX2015012520A MX2015012520A MX2015012520A MX 2015012520 A MX2015012520 A MX 2015012520A MX 2015012520 A MX2015012520 A MX 2015012520A MX 2015012520 A MX2015012520 A MX 2015012520A MX 2015012520 A MX2015012520 A MX 2015012520A
Authority
MX
Mexico
Prior art keywords
depression
subject
methods
selecting
treatment regimen
Prior art date
Application number
MX2015012520A
Other languages
English (en)
Inventor
Maurizio Fava
George Papakostas
Harold O Koch Jr
David Kronlage
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/796,362 external-priority patent/US9546401B2/en
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2015012520A publication Critical patent/MX2015012520A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención proporciona ensayos, métodos y composiciones para la selección de un régimen de tratamiento para un paciente que tenga depresión o en riesgo de depresión y/o tratar al menos un síntoma de depresión en el sujeto, con base en el reconocimiento de que combinaciones específicas de polimorfismos de un solo nucleótido (SNPs) están asociadas con una respuesta terapéutica a un compuesto que comprende folato. Tambiénse proporcionan en la presente métodos para mejorar la eficacia de un fármaco antidepresivo administrado a un sujeto con depresión o en riesgo de depresión mediante la administración de una terapia adyuvante de un compuesto que comprende folato al sujeto si el sujeto porta una combinación específica de SNPs que son predictivos de una respuesta terapéutica. Además, se proporcionan en la presente composiciones del compuesto que comprende folato.
MX2015012520A 2013-03-12 2014-03-11 Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion. MX2015012520A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361777650P 2013-03-12 2013-03-12
US13/796,362 US9546401B2 (en) 2011-11-14 2013-03-12 Assays and methods for selecting a treatment regimen for a subject with depression
US201361914338P 2013-12-10 2013-12-10
PCT/US2014/023695 WO2014164882A1 (en) 2013-03-12 2014-03-11 Assays and methods for selecting a treatment regimen for a subject with depression

Publications (1)

Publication Number Publication Date
MX2015012520A true MX2015012520A (es) 2016-01-12

Family

ID=51658998

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012520A MX2015012520A (es) 2013-03-12 2014-03-11 Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion.

Country Status (12)

Country Link
EP (1) EP2973135A4 (es)
JP (1) JP2016518816A (es)
KR (1) KR20150131147A (es)
CN (1) CN105518685A (es)
AU (1) AU2014248949A1 (es)
BR (1) BR112015022820A8 (es)
CA (1) CA2904418A1 (es)
IL (1) IL241156A0 (es)
MX (1) MX2015012520A (es)
RU (1) RU2015143177A (es)
TW (1) TW201437635A (es)
WO (1) WO2014164882A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013270422A1 (en) * 2012-06-01 2015-01-22 Brc Operations Pty Limited Biomakers for treatment outcomes
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
EP3229812A4 (en) 2014-12-08 2018-10-03 Glycom A/S Synthetic composition for treating metabolic disorders
WO2016135707A1 (en) * 2015-02-27 2016-09-01 Nestec S.A. Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders
WO2017071716A1 (en) 2015-10-28 2017-05-04 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
ES2927009T3 (es) 2015-10-28 2022-10-31 Glycom As Composición sintética y método para modular la función cerebral y la conducta
KR101911339B1 (ko) * 2017-07-17 2018-10-25 고려대학교 산학협력단 카테콜아민-o-메틸 전이 효소 유전자의 메틸화 비율을 이용한 우울증 진단에 관한 정보를 제공하는 방법
CN109234383A (zh) * 2018-11-07 2019-01-18 上海康黎医学检验所有限公司 与抗精神疾病药相关的试剂盒、目标基因及其制备、snp标记、snp识别和应用
CN109966498A (zh) * 2019-03-25 2019-07-05 北京坤秋健康科技有限公司 一种抗抑郁症的药物组合物及其用途
CN111500709A (zh) * 2020-05-12 2020-08-07 珠海横琴润孚创新科技有限公司 一种代谢性疾病基因检测与临床深度数据分析方法
KR102570458B1 (ko) * 2021-01-21 2023-08-24 전남대학교산학협력단 여성의 우울증 위험도 예측용 바이오마커, 상기 바이오마커를 이용한 여성의 우울증 위험도 진단에 대한 정보제공방법 및 진단키트
JP7432190B2 (ja) 2021-03-01 2024-02-16 勝彦 山▲崎▼ 抗うつ薬抵抗性の大うつ病患者を識別するための、データの取得方法およびキット
CN116103385A (zh) * 2021-11-11 2023-05-12 中国科学院深圳理工大学(筹) 一种预测抑郁障碍患者对治疗反应的基因诊断试剂盒和系统
WO2023237305A1 (en) 2022-06-09 2023-12-14 Société des Produits Nestlé S.A. Nutritional composition comprising gos and hmos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006099164A2 (en) * 2005-03-10 2006-09-21 Applera Corporation Methods for multiplex amplification
US20120115147A1 (en) * 2010-11-05 2012-05-10 Lombard Jay L Neuropsychiatric test reports
WO2010138796A2 (en) * 2009-05-29 2010-12-02 Genomind, Llc Methods for assessment and treatment of depression via utilization of single nucleotide polymorphisms analysis
CN102781259A (zh) * 2009-09-30 2012-11-14 加利福尼亚大学董事会 辅因子及个体使用方法
WO2012128799A2 (en) * 2010-12-03 2012-09-27 General Hospital Corporation, The Treating schizophrenia
MX354547B (es) * 2011-11-14 2018-03-09 Alfasigma Spa Ensayos y métodos para seleccionar un regimen de tratamiento para un sujeto con depresión.

Also Published As

Publication number Publication date
WO2014164882A1 (en) 2014-10-09
IL241156A0 (en) 2015-11-30
CA2904418A1 (en) 2014-10-09
KR20150131147A (ko) 2015-11-24
TW201437635A (zh) 2014-10-01
EP2973135A1 (en) 2016-01-20
BR112015022820A2 (pt) 2017-07-18
JP2016518816A (ja) 2016-06-30
RU2015143177A (ru) 2017-04-18
BR112015022820A8 (pt) 2019-11-26
CN105518685A (zh) 2016-04-20
AU2014248949A1 (en) 2015-09-10
EP2973135A4 (en) 2016-11-16

Similar Documents

Publication Publication Date Title
MX2015012520A (es) Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion.
AU2018253615A1 (en) Adeno-associated virus mediated gene transfer to the central nervous system
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
DOP2014000170A (es) Compuestos de imidazopirrolidinona
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
BR112015005227A2 (pt) inibidores de glicosilceramida sintase
BR112015020466A2 (pt) inibidores de cdc7
MX2020012924A (es) Terapias combinadas de coenzima q10 para el tratamiento de cancer.
MA32784B1 (fr) Composes aryles substitues par heterocycle comme inhibiteurs de hif
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2015003048A (es) Tratamiento del trastorno de estres post-traumatico con mycobacterium aislado.
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
ECSP13012551A (es) Terapia de combinación para tratar infección por hcv.
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112016028446A2 (pt) inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
BR112018010012A2 (pt) regimes de dosagem de melflufen para câncer
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
AR100734A1 (es) Método para tratar leucemia linfocítica crónica (cll)
MX2018004112A (es) Terapia de combinacion racional para el tratamiento de cancer.